peppersite
Peptide

Oxytocin Acetate

Oxytocin acetate is a lab-made copy of oxytocin, a nine-amino-acid hormone made in the hypothalamus. It is an approved medicine in obstetric care and is also studied, with mixed and often disappointing results, in research on social behaviour, mood and pain.

Researched for
Recovery

At a glance

Type
Peptide
Evidence
Not yet audited here; the reference library calls it emerging
Reported amount
200 mcg per Peptide Dosing Protocols. All 2 sources
Typical vial
5 mg in 3 mL

How much to draw

Full calculator →
Your draw
12units
0.12 mL on a U-100 insulin syringe
1.67 mg/mL25 doses per vial
Amount per dose

Opened on 200 mcg, the figure Peptide Dosing Protocols reports for Oxytocin Acetate, and a 5 mg vial in 3 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Oxytocin Acetate or for anything else, and nothing below has been checked against the study it came from.

24 IU intranasal (6 sprays of 4 IU each, 3 per nostril)
Frequency
Once or twice daily for research protocolsnonapeptide neurohormone produced in the h
Route
intranasal
Reported by
Peptide Protocol Wiki
Standard: 200-300 mcg · Low: 100 mcg · High: 400-500 mcg
Frequency
Once dailycycle Duration 1-2 weeks Review Point Week 2 Notes Used in mood, anxiety, and pain research blocks.
Route
Subcutaneous
Reported by
Peptide Dosing Protocols
What it saysHalf-life: about 3-6 minutes. The standard dosing for subcutaneous oxytocin is 200-300 mcg once daily.
Reconstitution, as reported
  • add 2-3 mL bacteriostatic water to a 2 mg or 5 mg lyophilized vial
Not yet audited

We have not published an audit on Oxytocin Acetate. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

Released into the bloodstream, oxytocin makes the womb contract in labour and triggers milk let-down. Released inside the brain, it acts on regions such as the amygdala and is linked to changes in social attention, trust and emotional response to faces. Researchers describe it binding the oxytocin receptor, a G-protein-coupled receptor that engages both excitatory and inhibitory pathways, which may be one reason its dose-response curves are not straight lines. It does not cross the blood-brain barrier easily, and the largest trial in autism found no benefit over placebo.

Reported side effects

Seen in studies: the FDA label for the IV and IM obstetric product lists over-strong contractions and rupture of the womb, bleeding after birth, water intoxication with seizures and coma tied to the drug's antidiuretic effect during long infusions, maternal heart rhythm and blood pressure changes, and fetal problems including slow heart rate and low oxygen. A 24-week trial in 290 children and adolescents reported no difference in serious adverse events between oxytocin and placebo.

Reported by users: in research use through the nose, mild nasal irritation, sneezing and a runny nose, short-lived headache or tiredness, and occasional irritability or mood changes, particularly at higher amounts. Injected under the skin, redness, bruising or soreness at the site.

Not ruled out: research-use vials vary in purity, and short peripheral spikes after injection under the skin come with no clear effect in the brain.

Who should avoid it

Pregnant people outside hospital-supervised induction: inappropriate use can rupture the womb or cause fetal distress.

People with cardiovascular disease or severe cardiac conditions: the FDA label notes risks of heart rhythm problems and water intoxication.

People with low blood sodium or on fluid restriction: oxytocin has antidiuretic activity that can cause water intoxication and seizures, especially during prolonged IV infusion.

People hypersensitive to oxytocin or to chlorobutanol, the preservative in some IV formulations: listed as a reason to avoid it.

Children and adolescents: use outside research settings is not supported by efficacy data.

People taking lithium, prostaglandin analogues or other agents affecting the womb or fluid balance: these are described as interacting.

What gets monitored

Continuous clinical monitoring during IV administration. (reported by Peptide Dosing Protocols)

Common questions

Is oxytocin FDA approved?

Yes for one set of uses and no for others. It is approved for obstetric uses such as inducing or strengthening labour and controlling bleeding after birth. It is not approved for the behavioural and psychiatric uses studied in research.

How much oxytocin is in 1 IU?

Reported amounts and schedules for oxytocin differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

What intranasal oxytocin amounts are used in research?

Reported amounts and schedules for oxytocin differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

Does subcutaneous oxytocin work like intranasal oxytocin?

Not for effects in the brain. Oxytocin does not cross the blood-brain barrier easily, so injection under the skin is not expected to reproduce what nasal dosing does centrally.

How long does oxytocin last after reconstitution?

Sources describe it as usable for roughly two to four weeks once mixed, provided it is stored properly.

Open the reconstitution calculator →

How do I reconstitute an oxytocin vial?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

Does the largest oxytocin trial in autism show it works?

No. The SOARS-B trial, with 290 children and adolescents over 24 weeks, found no significant difference from placebo on its main measure. No secondary social or cognitive measure reached significance either, and the lead author described the result as a major setback for the hypothesis.

Can oxytocin be used for anxiety, depression or PTSD?

It is not FDA-approved for any psychiatric condition. Small trials and reviews suggest possible reductions in amygdala reactivity in anxiety and PTSD, but no large Phase 3 evidence supports clinical use.

Sources

  1. 01U.S. Food and Drug Administration Oxytocin Injection, USP (synthetic) - Current FDA label (NDA 018261 / 018248). FDA Drugs@FDA (2022)
  2. 02U.S. Food and Drug Administration Pitocin (oxytocin injection, USP) - Prescribing information (NDA 018261). FDA Drugs@FDA (2021)
  3. 03Sikich L, Kolevzon A, King BH, McDougle CJ, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. New England Journal of Medicine (2021)
  4. 04Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature (2005)
  5. 05Quintana DS, Westlye LT, et al. Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Molecular Psychiatry / PMC (2021)
  6. 06Martins D, Brodmann K, Veronese M, et al. Less is more : a dose-response account of intranasal oxytocin pharmacodynamics in the human brain. bioRxiv (preprint, Imperial College London team) (2021)
  7. 07Higgins DT, Sutton MM, et al. Plasma pharmacokinetics of intravenous and intranasal oxytocin in nonpregnant adults. Peptides / PubMed (2025)
  8. 08Audunsdottir K, Sartorius AM, Kang H, et al. The effects of oxytocin administration on social and routinized behaviors in autism: a preregistered systematic review and meta-analysis. Psychoneuroendocrinology (2024)
  9. 09Ooi YP, Weng SJ, Kossowsky J, Gerger H, Sung M. Oxytocin and Autism Spectrum Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmacopsychiatry (2017)
  10. 10Keech B, Crowe S, Hocking DR. Intranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis. Psychoneuroendocrinology (2018)
  11. 11National Center for Biotechnology Information Oxytocin (Compound CID 439302) - structure and properties. PubChem (2026)
  12. 12Waltenspuhl Y, Schoppe J, Ehrenmann J, et al. Crystal structure of the human oxytocin receptor. Science Advances / bioRxiv preprint (2020)
  13. 13ClinicalTrials.gov (NICHD) SOARS-B: Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (NCT01944046). ClinicalTrials.gov (2021)

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things